Microbial metabolites direct the structural quality of brain protein aggregates, shifting them from amorphous toxic deposits to ordered, less harmful fibrils

Hypothesis

Specific gut‑derived metabolites—particularly butyrate and indole‑3‑propionic acid—alter the biophysical environment of the neuronal proteostasis network, promoting the formation of thermodynamically stable, ordered amyloid‑like fibrils rather than disordered, amorphous aggregates. This structural shift reduces proteotoxic stress and rescues cognitive function independent of total aggregate load.

Mechanistic Rationale

1. Metabolite‑dependent proteostasis tuning – Butyrate inhibits histone deacetylases, increasing expression of heat‑shock proteins (Hsp70, Hsp90) that favor ordered fibril elongation [4]. Indole‑3‑propionic acid acts as an antioxidant, lowering oxidative modifications that promote amorphous aggregation [3].
2. Lysosomal pH modulation – SCFAs raise lysosomal luminal pH, enhancing cathepsin activity and facilitating the clearance of misfolded monomers before they nucleate toxic species [1].
3. Tryptophan‑kynurenine balance – Strains that limit IDO1 activity raise tryptophan availability for serotonin synthesis, which stabilizes synaptic vesicles and reduces stress‑induced misfolding [2]. Together, these actions bias the aggregation pathway toward a structured fibrillar state that is less disruptive to membranes and synapses.

Experimental Design

• Model: Germ‑free mice colonized with defined bacterial consortia: (i) a butyrate‑producing Clostridium cluster XIVa strain, (ii) an indole‑3‑propionic acid‑producing Bacteroides strain, (iii) a control consortium lacking these metabolites.
• Intervention: 8‑week colonization, followed by intraperitoneal injection of amyloid‑β oligomers to seed aggregation.
• Readouts:
  • Aggregate morphology via cryo‑EM and thioflavin‑T vs. Congo‑red staining to quantify ordered fibrils vs. amorphous deposits.
  • Soluble oligomer levels by ELISA.
  • Synaptic protein markers (PSD‑95, synaptophysin) and hippocampal LTP.
  • Behavioral assays (Morris water maze, novel object recognition).
• Controls: Antibiotic‑treated mice and mice receiving metabolite supplementation (butyrate, indole‑3‑propionic acid) via gavage to confirm sufficiency.

Predictions and Falsifiability

• Prediction 1: Mice harboring metabolite‑producing strains will show a higher ratio of ordered fibrils to amorphous aggregates compared with controls, despite similar total amyloid‑β burden.
• Prediction 2: These mice will exhibit improved synaptic markers and cognitive performance relative to metabolite‑deficient colonsed mice.
• Falsification: If metabolite‑producing colonization does not alter aggregate ultrastructure (ordered vs. amorphous) or if cognitive rescue occurs without a detectable shift in aggregate quality, the hypothesis is refuted.

Implications

This framework reframes aggregate‑targeting therapies: rather than indiscriminately dissolving deposits, precision probiotics or metabolite supplements could be used to steer the proteome toward a safer, ordered state. It directly addresses the precision gap highlighted in current gut‑brain literature by linking specific microbial metabolites to the quality of protein aggregates, not merely their quantity.